Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, Larocca C, Saldanha SA, Abagyan R, Sun Y, Meyers DJ, Marmorstein R, Mahadevan LC, Alani RM, Cole PA.

Chem Biol. 2010 May 28;17(5):471-82. doi: 10.1016/j.chembiol.2010.03.006.


A novel exon in AML1-ETO negatively influences the clonogenic potential of the t(8;21) in acute myeloid leukemia.

Mannari D, Gascoyne D, Dunne J, Chaplin T, Young B.

Leukemia. 2010 Apr;24(4):891-4. doi: 10.1038/leu.2009.288. Epub 2010 Jan 28. No abstract available.


Balancing dormant and self-renewing hematopoietic stem cells.

Wilson A, Laurenti E, Trumpp A.

Curr Opin Genet Dev. 2009 Oct;19(5):461-8. doi: 10.1016/j.gde.2009.08.005. Epub 2009 Oct 5. Review.


Lysine acetylation targets protein complexes and co-regulates major cellular functions.

Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M.

Science. 2009 Aug 14;325(5942):834-40. doi: 10.1126/science.1175371. Epub 2009 Jul 16.


Post-translational modifications of Runx1 regulate its activity in the cell.

Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):30-4. doi: 10.1016/j.bcmd.2009.03.005. Epub 2009 Apr 21. Review.


Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Park S, Chen W, Cierpicki T, Tonelli M, Cai X, Speck NA, Bushweller JH.

Blood. 2009 Apr 9;113(15):3558-67. doi: 10.1182/blood-2008-06-161307. Epub 2009 Feb 9.


Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.

Kwok C, Zeisig BB, Qiu J, Dong S, So CW.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2853-8. doi: 10.1073/pnas.0810558106. Epub 2009 Feb 6.


Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.

Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, Pelicci PG.

Nature. 2009 Jan 1;457(7225):51-6. doi: 10.1038/nature07618.


RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.

Yan M, Ahn EY, Hiebert SW, Zhang DE.

Blood. 2009 Jan 22;113(4):883-6. doi: 10.1182/blood-2008-04-153742. Epub 2008 Nov 25.


t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.

Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE.

Blood. 2008 Aug 15;112(4):1392-401. doi: 10.1182/blood-2007-11-124735. Epub 2008 May 29.


Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.

Zhao X, Jankovic V, Gural A, Huang G, Pardanani A, Menendez S, Zhang J, Dunne R, Xiao A, Erdjument-Bromage H, Allis CD, Tempst P, Nimer SD.

Genes Dev. 2008 Mar 1;22(5):640-53. doi: 10.1101/gad.1632608.


Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells.

Jankovic V, Ciarrocchi A, Boccuni P, DeBlasio T, Benezra R, Nimer SD.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1260-5. Epub 2007 Jan 16.


A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE.

Nat Med. 2006 Aug;12(8):945-9. Epub 2006 Jul 30.


Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.

Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, Chen Z, Sun HD, Chen SJ.

Cell Death Differ. 2007 Feb;14(2):306-17. Epub 2006 Jun 16.


The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.

Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D, Lary J, Cole J, Dauter Z, Minor W, Speck NA, Bushweller JH.

Cancer Cell. 2006 Apr;9(4):249-60.


Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor.

Zheng Y, Balasubramanyam K, Cebrat M, Buck D, Guidez F, Zelent A, Alani RM, Cole PA.

J Am Chem Soc. 2005 Dec 14;127(49):17182-3.


The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor.

Wildonger J, Mann RS.

Development. 2005 May;132(10):2263-72. Epub 2005 Apr 13.


E protein silencing by the leukemogenic AML1-ETO fusion protein.

Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG.

Science. 2004 Aug 27;305(5688):1286-9.


Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.

Nimer SD, Moore MA.

Oncogene. 2004 May 24;23(24):4249-54. Review.


AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues.

Yamaguchi Y, Kurokawa M, Imai Y, Izutsu K, Asai T, Ichikawa M, Yamamoto G, Nitta E, Yamagata T, Sasaki K, Mitani K, Ogawa S, Chiba S, Hirai H.

J Biol Chem. 2004 Apr 9;279(15):15630-8. Epub 2004 Jan 29.

Supplemental Content

Support Center